YourChoice Therapeutics CEO Akash Bakshi (left) and CSO Nadja Mannowetz

Ex­clu­sive: Af­ter Covid piv­ot, biotech nabs funds to be first in the clin­ic with a non-hor­mon­al con­tra­cep­tive for men

The goal was to cre­ate a non-hor­mon­al con­tra­cep­tive that women could take to pre­vent preg­nan­cy and po­ten­tial­ly STIs, but the Covid-19 pan­dem­ic caused Your­Choice Ther­a­peu­tics to change course and even­tu­al­ly fo­cus most ef­forts on a non-hor­mon­al pill for men.

With Se­ries A fund­ing and a pre-IND meet­ing with the FDA un­der its belt, the biotech ex­pects to be the first com­pa­ny to en­ter the clin­ic with an in­ves­ti­ga­tion­al non-hor­mon­al con­tra­cep­tive for sperm-pro­duc­ers, with the goal of lim­it­ing sperm counts to in­fer­tile lev­els. A healthy vol­un­teer study in the US, if green­lit by the agency, will be­gin in the first half of next year, CEO Akash Bak­shi tells End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.